Bermuda Tech Week 2019 to Celebrate Innovation and Explore Opportunities for Growth
Registration is under way and filling fast for Bermuda Tech Week 2019 which will take place at the Hamilton Princess & Beach Club from October 14-18, 2019.
The programme of insightful and engaging events will explore future opportunities and challenges presented by emerging technologies such as artificial intelligence, blockchain, digital assets, insurtech and virtual reality. It will showcase Bermuda’s ongoing success in creating a welcoming, stable and well-regulated environment where technology and start-up companies can thrive.
“Bermuda has a long history of innovation so we understand and recognise the power of technology to positively impact both the economy and society,” said Bermuda Premier David Burt. “Over the past two years, we have built on our strength as a global leader in regulating the risks associated with the global insurance industry to develop a clear regulatory framework around managing the risks associated with Fintech. Our progressive approach has drawn accolades in U.S. Senate hearings and from an SEC commissioner in providing the kind of guidance, oversight and clarity needed for the industry to deliver on its mission to make financial services more accessible to people around the globe. Being at the forefront of innovation will help drive economic growth and job creation so we remain committed to being at the forefront of emerging trends, which is why we look forward to hosting Bermuda Tech Week 2019 in October.”
Andy Burrows, CEO of the Bermuda Business Development Agency (BDA), said: “Bermuda Tech Week 2019 comes at an ideal time and builds on the momentum we have seen in the market, driven by new and innovative legislation. Industry, government and regulatory authorities here in Bermuda work closely together to deliver an environment that facilitates progress. This is reflected in the programme of events that our team has put together. Our aim is for all attendees to come away with a better knowledge of how new technologies can be deployed to drive efficiencies in business and, importantly, what Bermuda has to offer the global market as a domicile of choice for tech companies and start-ups.”
At the heart of Bermuda Tech Week 2019 is the Bermuda Tech Summit which will take place on Wednesday, October 16 under the theme ‘Focused on the Future’. Bermuda’s Premier, David Burt, is set to deliver an opening address. Hosted by the BDA, in partnership with FinTech Bermuda, the all-day summit is free to attend and will explore the transformational impact of technology on investment and business models in a wide range of industry sectors relevant to Bermuda, from hospitality and financial services to telecommunications and insurance. Attendees will gain an in-depth understanding of how Bermuda’s business environment is facilitating innovation.
Events throughout the week will feature an array of speakers and attendees from across Bermuda’s government, industry and regulatory authorities along with some of the world’s most dynamic technology companies, including BitMEX, Blade, ChainThat, Circle, Data Innovation Labs, Flyt, Muckr.ai, SeaHeal, The Giving Block, Uulala, X and XBTO. Leading hotel brands AccorHotels (Fairmont), Hilton, Marriott International and Wyndham Hotel Group will also participate.
The schedule for Bermuda Tech Week 2019 includes:
- Liquidity Summit – a fintech event focused on leading and emerging trends across the world of finance. Presented by Hub Culture and the Ven digital currency, this event will take place on Monday, October 14 and Tuesday, October 15
- Defend and Detect – a technology and technique event hosted by KPMG Bermuda showcasing how technology and business ideas can come together to solve complex challenges in managing regulatory risk and compliance. This event is invitation-only and will take place on Tuesday, October 15
- Hello World – the world’s first AI to AI event hosted by Zeke.ai, Hub Culture’s emergent intelligent machine. This event will take place on Thursday, October 17
- Tech Beach ‘FinTech Innovation Island’ – coming to Bermuda for the first time, this will be an innovative space to explore opportunities for collaboration. Presented by Tech Beach, in partnership with the BDA and the Bermuda Tourism Authority (BTA), this event will be held on Thursday, October 17 and Friday, October 18
To register for events, visit www.bermudatechweek.bm, or if your company is interested in sponsoring or hosting additional events throughout the week, contact bermudatechweek@bda.bm. For a limited period only, take advantage of the $250/night preferred room rate at the Hamilton Princess & Beach Club by clicking here.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190820005544/en/
Contact information
Nicola Stevens
nstevens@bda.bm
+1 441 292 7774
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom